September 13th 2025
In STRIDE-13, the pneumococcal 21-valent conjugate vaccine (PCV21) induced robust immunogenicity in young, high-risk individuals against invasive pneumococcal disease.
FDA Receives 2 Supplemental Biologics License Applications for Guselkumab for Pediatric Indications
December 3rd 2024If approved, the new indications include children 6 years and older with moderate to severe plaque psoriasis and children 5 years and older with active juvenile psoriatic arthritis.
Read More
Childhood Pneumococcal Vaccination Programs Indirectly Protect Adults From Pneumococcal Disease
November 29th 2024Pneumococcal disease incidence decreased in adults after pneumococcal vaccines began to be used in children due to indirect protection, with fewer adults found to carry the bacterium that causes disease.
Read More
RSV Preventative Monoclonal Antibody Could Reduce Disease Incidence in Preterm, Full-term Infants
November 6th 2024Clesrovimab reduced RSV-associated hospitalizations and RSV-associated lower respiratory infection hospitalizations by more than 84% and 90% in preterm and full-term infants, respectively.
Read More